$ATAI
ATAI Life Sciences NV Stock $atai

$atai Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000095017022024162 Filed on November 10, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$38.00K	$24.00K	$266.0K
YoY Change	-83.48%	-90.98%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$15.73M	$19.42M	$20.26M
YoY Change	-39.22%	-4.17%	367.99%
% of Gross Profit
Research & Development	$21.88M	$19.03M	$13.36M
YoY Change	68.51%	42.39%	336.98%
% of Gross Profit
Depreciation & Amortization	$53.00K	$36.00K	-$7.000K
YoY Change	82.76%	-614.29%	-170.0%
% of Gross Profit
Operating Expenses	$37.60M	$38.45M	$33.63M
YoY Change	-3.23%	14.33%	355.28%
Operating Profit		-$38.42M	-$33.36M
YoY Change		15.17%	351.68%
Interest Expense	-$4.426M	$4.615M	$6.400M
YoY Change	21.06%	-27.89%	-4366.67%
% of Operating Profit
Other Income/Expense, Net	$2.670M	$5.289M	$6.887M
YoY Change	959.52%	-23.2%	-149.4%
Pretax Income	-$39.32M	-$33.13M	-$26.47M
YoY Change	-19.06%	25.16%	24.13%
Income Tax	$6.002M	$135.0K	$368.0K
% Of Pretax Income
Net Earnings	-$45.01M	-$33.89M	-$31.16M
YoY Change	-49.36%	8.76%	-62.55%
Net Earnings / Revenue	-118450.0%	-141195.83%	-11713.53%
Basic Earnings Per Share		-$0.22	-$0.21
Diluted Earnings Per Share	-$0.28	-$0.22	-$206.2K
COMMON SHARES
Basic Shares Outstanding	165.9M	161.8M	151.1M
Diluted Shares Outstanding		156.6M	151.1M

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$273.1M	$304.1M	$430.3M
YoY Change	-24.61%	-29.34%
Cash & Equivalents	$190.6M	$142.5M	$430.3M
Short-Term Investments	$82.50M	$161.5M
Other Short-Term Assets	$1.745M	$1.367M	$461.0K
YoY Change	130.82%	196.53%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$287.1M	$317.5M	$441.9M
YoY Change	-23.44%	-28.15%
LONG-TERM ASSETS
Property, Plant & Equipment	$928.0K	$728.0K	$138.0K
YoY Change	522.82%	427.54%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$0.00	$15.09M
YoY Change	-100.0%	-100.0%
Other Assets	$3.351M	$8.738M	$1.262M
YoY Change	-54.35%	592.39%
Total Long-Term Assets	$18.30M	$25.12M	$42.25M
YoY Change	-53.19%	-40.56%
TOTAL ASSETS
Total Short-Term Assets	$287.1M	$317.5M	$441.9M
Total Long-Term Assets	$18.30M	$25.12M	$42.25M
Total Assets	$305.4M	$342.6M	$484.1M
YoY Change	-26.25%	-29.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.399M	$3.511M	$1.974M
YoY Change	-60.04%	77.86%
Accrued Expenses	$17.31M	$22.14M	$13.08M
YoY Change	16.7%	69.35%
Deferred Revenue
YoY Change
Short-Term Debt	$82.50M	$161.5M	$38.00K
YoY Change		424900.0%
Long-Term Debt Due	$0.00	$0.00	$38.00K
YoY Change		-100.0%
Total Short-Term Liabilities	$19.90M	$25.91M	$15.32M
YoY Change	-4.96%	69.18%
LONG-TERM LIABILITIES
Long-Term Debt	$15.12M	$15.00M	$800.0K
YoY Change	1934.59%	1775.13%
Other Long-Term Liabilities	$3.708M	$3.695M	$3.285M
YoY Change	-9.49%	12.48%
Total Long-Term Liabilities	$3.708M	$3.695M	$3.285M
YoY Change	-9.49%	12.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.90M	$25.91M	$15.32M
Total Long-Term Liabilities	$3.708M	$3.695M	$3.285M
Total Liabilities	$39.68M	$46.52M	$21.35M
YoY Change	40.66%	117.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$510.2M	-$465.2M	-$268.9M
YoY Change	42.59%	72.99%
Common Stock	$18.56M	$18.55M	$17.87M
YoY Change	3.11%	3.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$260.7M	$289.4M	$453.2M
YoY Change
Total Liabilities & Shareholders Equity	$305.4M	$342.6M	$484.1M
YoY Change	-26.25%	-29.23%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$45.01M	-$33.89M	-$31.16M
YoY Change	-49.36%	8.76%	-62.55%
Depreciation, Depletion And Amortization	$53.00K	$36.00K	-$7.000K
YoY Change	82.76%	-614.29%	-170.0%
Cash From Operating Activities	-$30.50M	-$28.05M	-$28.11M
YoY Change	48.74%	-0.23%	93.17%
INVESTING ACTIVITIES
Capital Expenditures	$223.0K	-$529.0K	-$318.0K
YoY Change	-162.46%	66.35%	3433.33%
Acquisitions
YoY Change
Other Investing Activities	$80.27M	$66.58M	-$296.0K
YoY Change	-266.28%	-22592.91%	-98.79%
Cash From Investing Activities	$80.05M	$66.05M	-$614.0K
YoY Change	-264.6%	-10857.33%	-97.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-922.0K	19.78M	3.877M
YoY Change	-153.51%	410.21%	-87.52%
NET CHANGE
Cash From Operating Activities	-30.50M	-28.05M	-28.11M
Cash From Investing Activities	80.05M	66.05M	-614.0K
Cash From Financing Activities	-922.0K	19.78M	3.877M
Net Change In Cash	48.63M	57.79M	-24.85M
YoY Change	-172.12%	-332.57%	215.12%
FREE CASH FLOW
Cash From Operating Activities	-$30.50M	-$28.05M	-$28.11M
Capital Expenditures	$223.0K	-$529.0K	-$318.0K
Free Cash Flow	-$30.73M	-$27.52M	-$27.79M
YoY Change	52.48%	-0.99%	91.1%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	00-0000000
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	00000
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001840904
	atai	Deferred Financing Costs Included In Accounts Payable And Accrued Expenses DeferredFinancingCostsIncludedInAccountsPayableAndAccruedExpenses
CY2021Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1654
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1350
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40493
	dei	Entity Registrant Name EntityRegistrantName	ATAI Life Sciences N.V.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	P7
	dei	Entity Address Address Line1 EntityAddressAddressLine1	ATAI Life Sciences N.V.
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Wallstraße 16, 10179
	dei	Entity Address City Or Town EntityAddressCityOrTown	Berlin
	dei	Entity Address Country EntityAddressCountry	DE
	dei	City Area Code CityAreaCode	49 89
	dei	Local Phone Number LocalPhoneNumber	2153 9035
	dei	Security12b Title Security12bTitle	Common shares, par value €0.10 per share
	dei	Trading Symbol TradingSymbol	ATAI
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	165875307
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	142539000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	362266000
CY2022Q3	atai	Debt Securities Carried At Fair Value DebtSecuritiesCarriedAtFairValue	161518000
CY2021Q4	atai	Debt Securities Carried At Fair Value DebtSecuritiesCarriedAtFairValue	0
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13425000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11903000
CY2022Q3	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	0
CY2021Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	913000
CY2022Q3	us-gaap	Assets Current AssetsCurrent	317482000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	375082000
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	728000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	149000
CY2022Q3	us-gaap	Equity Method Investments EquityMethodInvestments	0
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	16131000
CY2022Q3	us-gaap	Other Long Term Investments OtherLongTermInvestments	8498000
CY2021Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	11628000
CY2022Q3	us-gaap	Notes Receivable Related Parties Noncurrent NotesReceivableRelatedPartiesNoncurrent	7151000
CY2021Q4	us-gaap	Notes Receivable Related Parties Noncurrent NotesReceivableRelatedPartiesNoncurrent	3835000
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8738000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7341000
CY2022Q3	us-gaap	Assets Assets	342597000
CY2021Q4	us-gaap	Assets Assets	414166000
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3511000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6004000
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	22142000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14829000
CY2022Q3	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	0
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	51000
CY2022Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	260000
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	51000
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	25913000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20935000
CY2022Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	1908000
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2432000
CY2022Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	380000
CY2021Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	743000
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3695000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4097000
CY2022Q3	us-gaap	Long Term Debt LongTermDebt	14621000
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	0
CY2022Q3	us-gaap	Liabilities Liabilities	46517000
CY2021Q4	us-gaap	Liabilities Liabilities	28207000
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.10
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.10
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.12
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.12
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	165875307
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	165875307
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	160677001
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	160677001
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	18554000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	18002000
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	761811000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	725045000
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-25788000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-8336000
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-465178000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-357803000
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	289399000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	376908000
CY2022Q3	us-gaap	Minority Interest MinorityInterest	6681000
CY2021Q4	us-gaap	Minority Interest MinorityInterest	9051000
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	296080000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	385959000
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	342597000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	414166000
CY2022Q3	us-gaap	Revenues Revenues	24000
CY2021Q3	us-gaap	Revenues Revenues	266000
	us-gaap	Revenues Revenues	195000
	us-gaap	Revenues Revenues	20146000
CY2022Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	19028000
CY2021Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	13363000
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	52437000
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	34974000
CY2022Q3	atai	Acquisition Of In Process Research And Development AcquisitionOfInProcessResearchAndDevelopment	0
CY2021Q3	atai	Acquisition Of In Process Research And Development AcquisitionOfInProcessResearchAndDevelopment	0
	atai	Acquisition Of In Process Research And Development AcquisitionOfInProcessResearchAndDevelopment	357000
	atai	Acquisition Of In Process Research And Development AcquisitionOfInProcessResearchAndDevelopment	8934000
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19419000
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20264000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	54623000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	66868000
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	38447000
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	33627000
	us-gaap	Operating Expenses OperatingExpenses	107417000
	us-gaap	Operating Expenses OperatingExpenses	110776000
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-38423000
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-33361000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-107222000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-90630000
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	145000
CY2021Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	8000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	361000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	80000
CY2022Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-430000
CY2021Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-469000
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-525000
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	191000
CY2022Q3	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0
CY2021Q3	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-41000
CY2022Q3	atai	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	0
CY2021Q3	atai	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	-47000
	atai	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	-53000
	atai	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	-87000
CY2022Q3	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	344000
CY2021Q3	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	0
	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	-981000
	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	0
CY2022Q3	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0
CY2021Q3	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-70000
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-5530000
CY2022Q3	atai	Gain Loss On Conversion Of Notes Related Party GainLossOnConversionOfNotesRelatedParty	0
CY2021Q3	atai	Gain Loss On Conversion Of Notes Related Party GainLossOnConversionOfNotesRelatedParty	0
	atai	Gain Loss On Conversion Of Notes Related Party GainLossOnConversionOfNotesRelatedParty	0
	atai	Gain Loss On Conversion Of Notes Related Party GainLossOnConversionOfNotesRelatedParty	-513000
CY2022Q3	us-gaap	Variable Interest Entity Initial Consolidation Gain Or Loss VariableInterestEntityInitialConsolidationGainOrLoss	0
CY2021Q3	us-gaap	Variable Interest Entity Initial Consolidation Gain Or Loss VariableInterestEntityInitialConsolidationGainOrLoss	0
	us-gaap	Variable Interest Entity Initial Consolidation Gain Or Loss VariableInterestEntityInitialConsolidationGainOrLoss	0
	us-gaap	Variable Interest Entity Initial Consolidation Gain Or Loss VariableInterestEntityInitialConsolidationGainOrLoss	3543000
CY2022Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	4470000
CY2021Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	6462000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	11515000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	5446000
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-100000
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-29000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-112000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-355000
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5289000
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6887000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	11361000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2608000
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-33134000
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-26474000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-95861000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-88022000
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	135000
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	368000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	227000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	432000
CY2022Q3	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	0
CY2021Q3	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	0
	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	0
	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	16923000
CY2022Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-2432000
CY2021Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-4800000
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-14680000
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-9440000
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-35701000
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-31642000
	us-gaap	Profit Loss ProfitLoss	-110768000
	us-gaap	Profit Loss ProfitLoss	-80971000
CY2022Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1814000
CY2021Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-484000
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3394000
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-2040000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-33887000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-31158000
	us-gaap	Net Income Loss NetIncomeLoss	-107374000
	us-gaap	Net Income Loss NetIncomeLoss	-78931000
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.69
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.69
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.59
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.59
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	156607468
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	156607468
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	151130212
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	151130212
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	154713922
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	154713922
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	134334685
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	134334685
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-35701000
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-31642000
	us-gaap	Profit Loss ProfitLoss	-110768000
	us-gaap	Profit Loss ProfitLoss	-80971000
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-4597000
CY2021Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-9158000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-17452000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-11074000
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-40298000
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-40800000
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-128220000
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-92045000
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	1814000
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	484000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	3394000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	2040000
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	48000
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	12000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	67000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	-22000
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-1766000
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-472000
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-3327000
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-2062000
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-38532000
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-40328000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-124893000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-89983000
CY2021Q4	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	385959000
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	132000
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10208000
CY2022Q1	atai	Foreign Currency Translation Adjustment Net Of Tax ForeignCurrencyTranslationAdjustmentNetOfTax	-4384000
CY2022Q1	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	-37558000
CY2022Q1	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	354357000
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1140000
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	118000
CY2022Q2	atai	Issuance Of Subsidiary Preferred Shares IssuanceOfSubsidiaryPreferredShares	600000
CY2022Q2	atai	Issuance Of Subsidiary Common Shares IssuanceOfSubsidiaryCommonShares	357000
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9511000
CY2022Q2	atai	Foreign Currency Translation Adjustment Net Of Tax ForeignCurrencyTranslationAdjustmentNetOfTax	-8452000
CY2022Q2	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	-37509000
CY2022Q2	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	320122000
CY2022Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	3773000
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1921000
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10515000
CY2022Q3	atai	Foreign Currency Translation Adjustment Net Of Tax ForeignCurrencyTranslationAdjustmentNetOfTax	-4549000
CY2022Q3	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	-35701000
CY2022Q3	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	296081000
CY2020Q4	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	95368000
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	4900000
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	23510000
CY2021Q1	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	885000
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	212000
CY2021Q1	atai	Foreign Currency Translation Adjustment Net Of Tax ForeignCurrencyTranslationAdjustmentNetOfTax	-4026000
CY2021Q1	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	4044000
CY2021Q1	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	119993000
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	4900000
CY2021Q2	atai	Settlement Of Issuance Of Common Shares Value SettlementOfIssuanceOfCommonSharesValue	140868000
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	9000000.0
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	231581000
CY2021Q2	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	3649000
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	37512000
CY2021Q2	atai	Foreign Currency Translation Adjustment Net Of Tax ForeignCurrencyTranslationAdjustmentNetOfTax	2110000
CY2021Q2	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	-50818000
CY2021Q2	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	484895000
CY2021Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	6424000
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12240000
CY2021Q3	atai	Foreign Currency Translation Adjustment Net Of Tax ForeignCurrencyTranslationAdjustmentNetOfTax	-9158000
CY2021Q3	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	-31641000
CY2021Q3	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	462760000
	us-gaap	Profit Loss ProfitLoss	-110768000
	us-gaap	Profit Loss ProfitLoss	-80971000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	115000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	18000
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	192000
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-525000
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	191000
	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	-981000
	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	0
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-0
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-41000
	atai	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	53000
	atai	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	-87000
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-5530000
	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	0
	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	16923000
	atai	Loss On Conversion Of Convertible Notes LossOnConversionOfConvertibleNotes	0
	atai	Loss On Conversion Of Convertible Notes LossOnConversionOfConvertibleNotes	513000
	us-gaap	Variable Interest Entity Initial Consolidation Gain Or Loss VariableInterestEntityInitialConsolidationGainOrLoss	0
	us-gaap	Variable Interest Entity Initial Consolidation Gain Or Loss VariableInterestEntityInitialConsolidationGainOrLoss	3543000
	atai	Income Losses From Equity Method Investments IncomeLossesFromEquityMethodInvestments	14680000
	atai	Income Losses From Equity Method Investments IncomeLossesFromEquityMethodInvestments	9440000
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	357000
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	8934000
	us-gaap	Share Based Compensation ShareBasedCompensation	30235000
	us-gaap	Share Based Compensation ShareBasedCompensation	49964000
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	9536000
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	8289000
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-158000
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	43000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1778000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	9657000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2436000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1671000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4924000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3266000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	180000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-73962000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-42737000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	631000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	121000
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	170000
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	650000
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	256554000
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	94055000
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	47000
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	5362000
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	600000
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	23659000
	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties	3000000
	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties	2625000
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	0
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	273000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-166900000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-32643000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	409884000
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	12350000
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	534000
	atai	Proceeds From Sale Of Investment ProceedsFromSaleOfInvestment	0
	atai	Proceeds From Sale Of Investment ProceedsFromSaleOfInvestment	2417000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2171000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0
	us-gaap	Proceeds From Issuance Of Trust Preferred Securities ProceedsFromIssuanceOfTrustPreferredSecurities	600000
	us-gaap	Proceeds From Issuance Of Trust Preferred Securities ProceedsFromIssuanceOfTrustPreferredSecurities	0
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	4635000
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	6067000
	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	15000000
	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	0
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	699000
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	1587000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	21707000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	408139000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-572000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-303000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-219727000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	333062000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	362266000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	97246000
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	142539000
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	430308000
	atai	Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities	487000
	atai	Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities	0
	atai	Issuance Of Subsidiary Shares In Connection With A Stock Purchase Agreement IssuanceOfSubsidiarySharesInConnectionWithAStockPurchaseAgreement	357000
	atai	Issuance Of Subsidiary Shares In Connection With A Stock Purchase Agreement IssuanceOfSubsidiarySharesInConnectionWithAStockPurchaseAgreement	0
	atai	Deferred Financing Costs Included In Accounts Payable And Accrued Expenses DeferredFinancingCostsIncludedInAccountsPayableAndAccruedExpenses	1046000
	atai	Issuance Of Derivative Instrument Related To Convertible Promissory Notes IssuanceOfDerivativeInstrumentRelatedToConvertiblePromissoryNotes	0
	atai	Issuance Of Derivative Instrument Related To Convertible Promissory Notes IssuanceOfDerivativeInstrumentRelatedToConvertiblePromissoryNotes	646000
	atai	Fair Value Of Non Controlling Interests Issued In Connection With Consolidation Of Variable Interest Entity FairValueOfNonControllingInterestsIssuedInConnectionWithConsolidationOfVariableInterestEntity	0
	atai	Fair Value Of Non Controlling Interests Issued In Connection With Consolidation Of Variable Interest Entity FairValueOfNonControllingInterestsIssuedInConnectionWithConsolidationOfVariableInterestEntity	392000
	atai	Fair Value Of Redeemable Non Controlling Interests Issued In Connection With Consolidation Of Variable Interest Entity FairValueOfRedeemableNonControllingInterestsIssuedInConnectionWithConsolidationOfVariableInterestEntity	0
	atai	Fair Value Of Redeemable Non Controlling Interests Issued In Connection With Consolidation Of Variable Interest Entity FairValueOfRedeemableNonControllingInterestsIssuedInConnectionWithConsolidationOfVariableInterestEntity	2555000
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	0
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	885000
	atai	Issuance Of Subsidiary Shares In Connection With The Conversion Of Convertible Notes IssuanceOfSubsidiarySharesInConnectionWithTheConversionOfConvertibleNotes	0
	atai	Issuance Of Subsidiary Shares In Connection With The Conversion Of Convertible Notes IssuanceOfSubsidiarySharesInConnectionWithTheConversionOfConvertibleNotes	3258000
	us-gaap	Nature Of Operations NatureOfOperations	<p id="footnotes" style="text-indent:0.0%;font-size:10.0pt;margin-top:4.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1. Or</span><span id="notes"/><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">ganization and Description of Business</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;line-height:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">ATAI Life Sciences N.V. (“atai”) is the parent company of ATAI Life Sciences AG and, along with its subsidiaries, is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to acquiring, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.75pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Since inception, atai has either created wholly owned subsidiaries or has made investments in certain controlled entities, including variable interest entities (“VIEs”) for which atai is the primary beneficiary under the VIE model (collectively, the “Company”). atai is headquartered in Berlin, Germany.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company has determined that it has one operating and reporting segment.</span></p><p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Corporate Reorganization and Initial Public Offering</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.4pt;line-height:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">atai was incorporated pursuant to the laws of the Netherlands as a Dutch private company with limited liability on September 10, 2020 for the purposes of becoming a holding company for ATAI Life Sciences AG and consummating the corporate reorganization described below. atai did not conduct any operations prior to the corporate reorganization other than activities incidental to its formation. ATAI Life Sciences AG was formed as a separate company on February 7, 2018.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.85pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">In contemplation of the consummation of atai’s initial public offering (“IPO”) of common shares, atai undertook a corporate reorganization (the “Corporate Reorganization”). The Corporate Reorganization consisted of several steps as described below:</span></p><div style="margin-left:5.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:5.065%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.335229367461947%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Exchange of ATAI Life Sciences AG Securities for ATAI Life Sciences B.V. Common Shares and Share Split</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">: In April 2021, the existing shareholders of ATAI Life Sciences AG each became a party to a separate notarial deed of issue under Dutch law and (i) subscribed for new common shares in ATAI Life Sciences B.V. and (ii) transferred their respective shares in ATAI Life Sciences AG, on a </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1 to 10 basis</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> (the “Exchange Ratio”), to ATAI Life Sciences B.V. as a contribution in kind on the common shares in ATAI Life Sciences B.V. As a result of the issuance of common shares in ATAI Life Sciences B.V. to the shareholders of ATAI Life Sciences AG and the contribution and transfer of their respective shares in ATAI Life Sciences AG to ATAI Life Sciences B.V., ATAI Life Sciences AG became a wholly owned subsidiary of ATAI Life Sciences B.V. No shareholder rights or preferences changed as a result of the share for share exchange. In connection with such exchange, the common share in ATAI Life Sciences B.V. held by Apeiron was cancelled. On June 7, 2021, shares of ATAI Life Sciences B.V. were split applying a ratio of </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.6 to one</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">, and the nominal value of the shares was reduced to €</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">, pursuant to a shareholders’ resolution and amendment to the articles of association.</span></div></div><div style="margin-left:5.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:5.065%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.335229367461947%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Conversion of ATAI Life Sciences B.V. into ATAI Life Sciences N.V</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">.: Immediately preceding the Company’s IPO, the legal form of ATAI Life Sciences B.V. was converted from a Dutch private company with limited liability to a Dutch public company, and the articles of association of ATAI Life Sciences N.V., became effective. Following the Corporate Reorganization, ATAI Life Sciences N.V. became the holding company of ATAI Life Sciences AG.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.85pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1452083333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Corporate Reorganization, as described above, is considered a continuation of ATAI Life Sciences AG resulting in no change in the carrying values of assets or liabilities. As a result, the financial statements for periods prior to the Corporate Reorganization are the financial statements of ATAI Life Sciences AG as the predecessor to atai for accounting and reporting purposes. All share, per-share and related information presented in these condensed consolidated financial statements and corresponding disclosure notes have been retrospectively adjusted, where applicable, to reflect the impact of the share exchange and share split resulting from the Corporate Reorganization. In connection with the Corporate Reorganization, outstanding share awards and option grants of ATAI Life Sciences AG were exchanged for share awards and option grants of ATAI Life Sciences B.V. with identical restrictions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1452083333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">On June 22, 2021, atai closed the IPO of its common shares on the Nasdaq Stock Market ("Nasdaq"). As part of the IPO, the Company issued and sold </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">17,250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> shares of its common shares, which included </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2,250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> shares sold pursuant to the exercise of the underwriters’ over-allotment option, at a public offering price of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">15.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> per share. The Company received net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">231.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million from the IPO, after deducting underwriters’ discounts and commissions of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">18.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million and offering costs of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">9.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million.</span></p><p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Impact of COVID-19 Pandemic</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;line-height:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1452083333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The COVID-19 pandemic has continued to present global public health and economic challenges during the nine months ended September 30, 2022. Although some research and development timelines have been impacted by delays related to the COVID-19 pandemic, the Company has not experienced material financial impacts on its business and operations as a result. The Company continues to monitor the impact of the COVID-19 pandemic on its employees and business and has undertaken business continuity measures to mitigate potential disruption to its operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The future impact of COVID-19 on the Company’s business and operations, including its research and development programs and related clinical trials, will largely depend on future developments, which are highly uncertain, such as the duration of the pandemic, the spread of the disease and variants thereof, the availability and effectiveness of vaccines and related roll-out efforts, breakthrough infections among the vaccinated, vaccine hesitancy, the implementation of vaccine mandates, travel restrictions, social distancing and related government actions around the world, business closures or business disruptions and the ultimate impact of COVID-19 on financial markets and the global economy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p><p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Liquidity and Going Concern</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;line-height:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company has incurred significant losses and negative cash flows from operations since its inception. As of September 30, 2022, the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Company had cash and cash equivalents of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">142.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million, short-term securities of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">161.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million and its accumulated deficit was $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">465.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million. The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Company has historically financed its operations through the sale of equity securities, debt financings, sale of convertible notes and revenue generated from licensing and collaboration arrangements. The Company has not generated any revenues to date from the sale of its product candidates and does not anticipate generating any revenues from the sale of its product candidates unless and until it successfully completes development and obtains regulatory approval to market its product candidates.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.75pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company currently expects that its existing cash and cash equivalents and short-term securities as of September 30, 2022 will be </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date the condensed consolidated financial statements are issued.</span></p>
	us-gaap	Common Stock Conversion Basis CommonStockConversionBasis	1 to 10 basis
CY2021Q2	us-gaap	Common Stock Conversion Basis CommonStockConversionBasis	1.6 to one
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.10
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	142500000
CY2022Q3	us-gaap	Short Term Borrowings ShortTermBorrowings	161500000
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-465200000
	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:11.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;line-height:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include, but are not limited to the fair value of the Company’s investment in Intelgenx Technologies Corp. (“IntelGenx”), securities carried at fair value, contingent consideration liability—related parties, in-process research and development assets (“IPRD”), redeemable noncontrolling interests and noncontrolling interests recognized in acquisitions, the valuations of common shares prior to IPO and share-based awards, and accruals for research and development costs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions.</span></p>
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	200000
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	255573000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0
CY2022Q3	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	16800000
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	100000
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	100000
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2200000
CY2021Q4	us-gaap	Minority Interest MinorityInterest	9051000
CY2022Q1	atai	Net Income Loss Attributable To Noncontrolling Interest Preferred NetIncomeLossAttributableToNoncontrollingInterestPreferred	-689000
CY2022Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	-11000
CY2022Q1	us-gaap	Minority Interest MinorityInterest	8351000
CY2022Q2	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	957000
CY2022Q2	atai	Net Income Loss Attributable To Noncontrolling Interest Preferred NetIncomeLossAttributableToNoncontrollingInterestPreferred	-891000
CY2022Q2	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	30000
CY2022Q2	us-gaap	Minority Interest MinorityInterest	8447000
CY2022Q3	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	0
CY2022Q3	atai	Net Income Loss Attributable To Noncontrolling Interest Preferred NetIncomeLossAttributableToNoncontrollingInterestPreferred	-1456000
CY2022Q3	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	48000
CY2022Q3	us-gaap	Minority Interest MinorityInterest	6681000
CY2020Q4	us-gaap	Minority Interest MinorityInterest	4546000
CY2021Q1	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	885000
CY2021Q1	atai	Net Income Loss Attributable To Noncontrolling Interest Common NetIncomeLossAttributableToNoncontrollingInterestCommon	870000
CY2021Q1	atai	Net Income Loss Attributable To Noncontrolling Interest Preferred NetIncomeLossAttributableToNoncontrollingInterestPreferred	2486000
CY2021Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	-184000
CY2021Q1	us-gaap	Minority Interest MinorityInterest	8603000
CY2021Q2	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	3649000
CY2021Q2	atai	Net Income Loss Attributable To Noncontrolling Interest Common NetIncomeLossAttributableToNoncontrollingInterestCommon	-2364000
CY2021Q2	atai	Net Income Loss Attributable To Noncontrolling Interest Preferred NetIncomeLossAttributableToNoncontrollingInterestPreferred	7000
CY2021Q2	us-gaap	Minority Interest MinorityInterest	10045000
CY2021Q3	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	0
CY2021Q3	atai	Net Income Loss Attributable To Noncontrolling Interest Common NetIncomeLossAttributableToNoncontrollingInterestCommon	0
CY2021Q3	atai	Net Income Loss Attributable To Noncontrolling Interest Preferred NetIncomeLossAttributableToNoncontrollingInterestPreferred	-483000
CY2021Q3	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	12000
CY2021Q3	us-gaap	Minority Interest MinorityInterest	9574000
CY2021Q2	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	150000
CY2022Q3	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	0
CY2021Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	0
CY2020Q4	us-gaap	Redeemable Noncontrolling Interest Equity Redemption Value RedeemableNoncontrollingInterestEquityRedemptionValue	0
CY2021Q1	atai	Issuance Of Redeemable Noncontrolling Interests IssuanceOfRedeemableNoncontrollingInterests	0
CY2021Q1	atai	Net Loss Attributable To Redeemable Noncontrolling Interests Common NetLossAttributableToRedeemableNoncontrollingInterestsCommon	0
CY2021Q1	us-gaap	Redeemable Noncontrolling Interest Equity Redemption Value RedeemableNoncontrollingInterestEquityRedemptionValue	0
CY2021Q2	atai	Issuance Of Redeemable Noncontrolling Interests IssuanceOfRedeemableNoncontrollingInterests	2555000
CY2021Q2	atai	Net Loss Attributable To Redeemable Noncontrolling Interests Common NetLossAttributableToRedeemableNoncontrollingInterestsCommon	-2555000
CY2021Q2	us-gaap	Redeemable Noncontrolling Interest Equity Redemption Value RedeemableNoncontrollingInterestEquityRedemptionValue	0
CY2021Q3	atai	Issuance Of Redeemable Noncontrolling Interests IssuanceOfRedeemableNoncontrollingInterests	0
CY2021Q3	atai	Net Loss Attributable To Redeemable Noncontrolling Interests Common NetLossAttributableToRedeemableNoncontrollingInterestsCommon	0
CY2021Q3	us-gaap	Redeemable Noncontrolling Interest Equity Redemption Value RedeemableNoncontrollingInterestEquityRedemptionValue	0
CY2022Q3	us-gaap	Variable Interest Entity Entity Maximum Loss Exposure Amount VariableInterestEntityEntityMaximumLossExposureAmount	8500000
CY2022Q3	us-gaap	Variable Interest Difference Between Carrying Amount And Maximum Exposure VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure	7100000
CY2021Q4	us-gaap	Variable Interest Entity Entity Maximum Loss Exposure Amount VariableInterestEntityEntityMaximumLossExposureAmount	11600000
CY2021Q4	us-gaap	Variable Interest Difference Between Carrying Amount And Maximum Exposure VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure	3800000
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	16131000
CY2022Q3	us-gaap	Other Long Term Investments OtherLongTermInvestments	8498000
CY2021Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	11628000
	atai	Equity Method Investment Shares Transaction Date EquityMethodInvestmentSharesTransactionDate	2026-12-31
	us-gaap	Subsidiary Or Equity Method Investee Cumulative Proceeds Received On All Transactions SubsidiaryOrEquityMethodInvesteeCumulativeProceedsReceivedOnAllTransactions	9600000
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	2100000
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0
CY2021Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	3000000.0
CY2021Q4	atai	Fair Value Of Common Stock By Applying Discount For Lack Of Marketability FairValueOfCommonStockByApplyingDiscountForLackOfMarketability	0.050
CY2022Q3	atai	Fair Value Of Common Stock By Applying Discount For Lack Of Marketability FairValueOfCommonStockByApplyingDiscountForLackOfMarketability	0.050
CY2022Q3	atai	Accrued External Research And Development Expenses Current AccruedExternalResearchAndDevelopmentExpensesCurrent	5126000
CY2022Q3	atai	Term Loan Impairment Loss Recognized TermLoanImpairmentLossRecognized	0
CY2022Q3	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	100000
CY2021Q4	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	100000
CY2022Q3	atai	Prepaid Research And Development Related Expenses PrepaidResearchAndDevelopmentRelatedExpenses	3404000
CY2021Q4	atai	Prepaid Research And Development Related Expenses PrepaidResearchAndDevelopmentRelatedExpenses	2692000
CY2022Q3	us-gaap	Prepaid Taxes PrepaidTaxes	5352000
CY2021Q4	us-gaap	Prepaid Taxes PrepaidTaxes	5406000
CY2022Q3	us-gaap	Prepaid Insurance PrepaidInsurance	3302000
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	3049000
CY2022Q3	us-gaap	Other Assets Current OtherAssetsCurrent	1367000
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	756000
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13425000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11903000
CY2022Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	5392000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2667000
CY2022Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	6677000
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	8137000
CY2021Q4	atai	Accrued External Research And Development Expenses Current AccruedExternalResearchAndDevelopmentExpensesCurrent	861000
CY2022Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	3989000
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2832000
CY2022Q3	atai	Accrued Advisory Fees Current AccruedAdvisoryFeesCurrent	0
CY2021Q4	atai	Accrued Advisory Fees Current AccruedAdvisoryFeesCurrent	169000
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	958000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	163000
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	22142000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14829000
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-5000
CY2022Q3	us-gaap	Convertible Debt ConvertibleDebt	380000
CY2021Q4	us-gaap	Convertible Debt ConvertibleDebt	743000
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	200000
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	200000
CY2022Q3	us-gaap	Loans Held For Sale Maturity Date LoansHeldForSaleMaturityDate	2026-08-01
	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	175000000.0
CY2022Q3	atai	Prime Rate Percent PrimeRatePercent	0.0455
CY2022Q3	atai	Accrued Interest Payable AccruedInterestPayable	0.0855
CY2022Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	15000000
CY2022Q3	atai	End Of The Term Charge EndOfTheTermCharge	1042000
CY2022Q3	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	-291000
CY2022Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-120000
CY2022Q3	atai	Unamortized End Of Term Charge UnamortizedEndOfTermCharge	-1010000
CY2022Q3	us-gaap	Certain Loans Acquired In Transfer Accounted For As Debt Securities Carrying Amount Net CertainLoansAcquiredInTransferAccountedForAsDebtSecuritiesCarryingAmountNet	14621000
CY2022Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	0
CY2022Q3	us-gaap	Long Term Debt LongTermDebt	14621000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	154713922
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	134334685
CY2021Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	152200000
CY2021Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4900000
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	18933464
CY2022Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	3300000
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	400000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	200000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	400000
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-35701000
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-31642000
	us-gaap	Profit Loss ProfitLoss	-110768000
	us-gaap	Profit Loss ProfitLoss	-80971000
CY2022Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1814000
CY2021Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-484000
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3394000
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-2040000
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-33887000
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-33887000
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-31158000
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-31158000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-107374000
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-107374000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-78931000
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-78931000
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	156607468
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	156607468
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	151130212
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	151130212
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	154713922
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	134334685
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.69
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.69
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.59
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.59
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	46782562
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	43002672
	us-gaap	Lease Cost LeaseCost	1800000
CY2020Q3	atai	Related Party Reservation Rate Of Common Shares For Ipo RelatedPartyReservationRateOfCommonSharesForIpo	0.27
	us-gaap	Variable Interest Entity Ownership Percentage VariableInterestEntityOwnershipPercentage	0.565

Files In Submission

Name	View Source	Status
0000950170-22-024162-index-headers.html	Edgar Link	pending
0000950170-22-024162-index.html	Edgar Link	pending
0000950170-22-024162.txt	Edgar Link	pending
0000950170-22-024162-xbrl.zip	Edgar Link	pending
atai-20220930.htm	Edgar Link	pending
atai-20220930.xsd	Edgar Link	pending
atai-ex10_2.htm	Edgar Link	pending
atai-ex31_1.htm	Edgar Link	pending
atai-ex31_2.htm	Edgar Link	pending
atai-ex32_1.htm	Edgar Link	pending
atai-ex32_2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img105020950_0.jpg	Edgar Link	pending
img194914858_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
atai-20220930_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
atai-20220930_lab.xml	Edgar Link	unprocessable
atai-20220930_pre.xml	Edgar Link	unprocessable
atai-20220930_htm.xml	Edgar Link	completed
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
atai-20220930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ATAI
ATAI Life Sciences NV Stock $atai

2022 Q4 Form 10-Q Financial Statement

#000095017022024162 Filed on November 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATAI ATAI Life Sciences NV Stock $atai

2022 Q4 Form 10-Q Financial Statement

#000095017022024162 Filed on November 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATAI
ATAI Life Sciences NV Stock $atai